

Draft Guidance on Lamivudine; Tenofovir Disoproxil Fumarate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Lamivudine; Tenofovir disoproxil fumarate

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 300 mg; 300 mg
Subjects: Males and non-pregnant, non-lactating females, general population
Additional comments: None

2. Type of study: Fed
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: 300 mg; 300 mg
Subjects: Males and non-pregnant, non-lactating females, general population
Additional comments: None

Analytes to measure (in appropriate biological fluid): Lamivudine and tenofovir in plasma

Bioequivalence based on (90% CI): Lamivudine and tenofovir

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).